A comprehensive analysis published in The Lancet on Monday (16) reveals that cannabis-derived medications demonstrate limited effectiveness in addressing a variety of mental health disorders and substance misuse problems. This review consolidates findings from 54 randomized clinical trials conducted between 1980 and May 2025, engaging a total of 2,477 participants. Researchers aimed to evaluate cannabinoids as a primary treatment option for mental disorders and substance use disorders.

The review specifically scrutinized commonly cited reasons for utilizing medicinal cannabis, such as for anxiety disorders, PTSD, and sleep issues. Despite an increase in medicinal cannabis use in countries like the United States, Canada, and Australia, where numerous patients report anecdotal success, the study did not find significant benefits across the diverse range of mental health conditions assessed. This highlights a critical gap between popular belief and empirical evidence regarding the therapeutic viability of cannabis in treating such disorders.

The implications of this research are profound, especially as the legalization and acceptance of cannabis for medicinal use continue to grow worldwide. It raises essential questions about regulatory frameworks, clinical recommendations, and the need for continued research to explore alternative treatments for mental health disorders, potentially guiding better patient care in the future.